Med BioGene Swings to Loss, Posts No Revenue for First-Half 2012 | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene on Thursday reported that it swung to a loss from a profit for the first half of 2012.

The Vancouver, British Columbia-based molecular diagnostics developer also said that it recorded no revenues for the six months ended June 30, compared to revenues of C$593,714 (US$597,795) for the first half of 2011, all of which were derived from licensing deals.

Its net loss for the first half of 2012 was C$223,418, or C$.00 per share, compared to a profit of C$215,034, or C$.00 per share, for the first half of 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.